Home News Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

BioInvent immunotherapy 2.0

Top oncologist underscores BioInvent’s potential for “Immunotherapy 2.0”

1 July, 2024

BioInvent recently announced promising clinical data for its lead cancer immunotherapy candidates, BI-1808 and BI-1206. The company hosted a Key Opinion Leader webinar to explain the results in detail, featuring insights from internationally recognized oncologist Dr Alexander Eggermont. According to Dr Eggermont, BioInvent’s candidates hold great promise for the future of immuno-oncology.

BioInvent has developed several cancer immunotherapy candidates currently in clinical development, both as monotherapy and in combination with today’s standard treatments. The two lead drug candidates, BI-1206, an anti-FcyRIIB antibody, and BI-1808, an anti-TNFR2 antibody, are being evaluated in phase I/IIa studies. BI-1206 is being explored in non-Hodgkin’s lymphoma (NHL) as well as solid tumours, while BI-1206 being evaluated in solid tumours only.

Positive data presented at recent conferences

This past month, the company has presented three significant data sets regarding both candidates at two major immune-oncology conferences: the American Society for Clinical Oncology’s (ASCO), and the European Hematology Association’s (EHA) annual meeting.

At ASCO, BioInvent presented two posters. The first detailed the initial positive efficacy data from the trial with BI-1808, both as single agent, and in combination with MSD’s anti-PD-1 checkpoint inhibitor Keytruda (pembrolizumab), in patients with advanced malignancies. Initial efficacy and safety data from the ongoing phase I/IIa study show one complete response (CR), one ongoing partial response (PR), and nine patients with stable disease (SD) in the single agent arm of BI-1808 as well as promising signs of efficacy and favourable safety profile in the phase I dose escalation part studying BI-1808 in combination with Keytruda.

The second poster showcased positive data from the study with BI-1206 in combination with Keytruda for the treatment of patients with solid tumours that have already undergone anti-PD-1/L1 treatment. The data show that BI-1206 in combination with pembrolizumab leads to responses in melanoma patients who had previously failed on anti-PD1/PDL1 therapy. The promising clinical efficacy signals in these heavily pre-treated patients include one complete response (CR), one long-lasting partial response (PR) in a patient with uveal melanoma -a hard-to-treat disease, and seven patients with stable disease (SD) including one long-lasting, out of 24 evaluable patients.

Meanwhile, at the EHA congress, the company presented promising clinical data for BI-1206 in relapsed/refractory (R/R) NHL dosed in combination with anti-CD20 antibody rituximab, which is the current standard of care in NHL. The data showcased results from the subcutaneous administration of BI-1206, with currently one complete response, two partial responses and one patient with stable disease, out of four evaluable patients. Read more here.

KOL event deep dives into promise of BioInvent pipeline.

BioInvent hosted a virtual KOL event last week to explain the data from both candidates in more detail, putting on full display the potential of FcgRIIB and TNFR2 as critical targets in cancer immunotherapy. To address this potential and discuss the role of BioInvent in the future of immunotherapy, the company invited leading KOL Dr Alexander Eggermont to speak at the event.

Dr Eggermont is an internationally recognised expert in oncology and immunotherapy with extensive experience in immunotherapy cancer research and drug development. He currently serves as the Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology and holds several professorships across Europe. Dr Eggermont’s involvement underscores the scientific credibility and potential impact of BioInvent’s programmes.

– It’s clear that BioInvent has a highly original programme with promising new agents, and that’s because they have common denominators that are essential in improving immunotherapies, says Dr Eggermont.

BioInvent potentially at the forefront of Immunotherapy 2.0 and the neoadjuvant revolution

During his presentation, Dr Eggermont presented the concept of “Immunotherapy 2.0” and the “neoadjuvant revolution,” highlighting a new era in cancer treatment focused on overcoming current limitations in immunotherapy.

– What is immunotherapy 2.0? Get in early (before surgery)! Go into first line as your goal and develop triplets in immunotherapy.

According to Dr Eggermont, all of BioInvent’s candidates have the potential to enhance any double or triple immunotherapy combination because of their optimal safety profile, so they are good candidates for what he calls immunotherapy 2.0.

– BioInvent’s agents break through the tumour’s immunsuppressive mechanisms, and are thereby quite unique, so they have all the building blocks to construct our immunotherapy 2.0.

Together with Dr Eggermont’s analysis, the latest results presented at ASCO and EHA reinforce BioInvent’s potential to make significant contributions to cancer treatment.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev